To assess whether AZD1208 synergizes with p38 inhibitors, we treated resistant AML (OCI-M1, OCI-M2), DLBCL (U2932, TMD8), and chronic myeloid leukemia (CML) (K562) cell lines with the combination of AZD1208 and the p38 inhibitors SB202190 or SCIO-469 (the latter is in phase II clinical trial for multiple myeloma: NCT00095680) (Figure 2A-2E and Figure S2A-S2C). This evidence concerns the gene MAPK14 and acute myeloid leukemia.